Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the role of tumor mutational burden (TMB) as biomarker in non-small cell lung cancer (NSCLC). Due to the heterogeneity of tumors that will have varying TMB, a pan-tumor threshold may lead to inaccurate results. Studies have alternatively shown a link between a high TMB and higher progression-free survival when receiving immunotherapy, which may be due to higher immunogenicity in these patients. TMB has additionally found to be independent of PD-L1 status, emphasizing the need to personalize treatment across subgroups. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Biagio Ricciuti, MD, is a consultant/advisory board for Regeneron.